Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
366 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Neuroblastoma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Pipeline Review, H2 2016, provides an overview of the Neuroblastoma (Oncology) pipeline landscape. Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 15, 15, 1, 43 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 7, 9 and 4 molecules, respectively.Neuroblastoma. Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 5 Neuroblastoma Overview 6 Therapeutics Development 7 Neuroblastoma - Therapeutics under Development by Companies 9 Neuroblastoma - Therapeutics under Investigation by Universities/Institutes 13 Neuroblastoma - Pipeline Products Glance 15 Neuroblastoma - Products under Development by Companies 18 Neuroblastoma - Products under Investigation by Universities/Institutes 23 Neuroblastoma - Companies Involved in Therapeutics Development 25 Neuroblastoma - Therapeutics Assessment 77 Drug Profiles 95 Neuroblastoma - Dormant Projects 338 Neuroblastoma - Discontinued Products 342 Neuroblastoma - Product Development Milestones 343 Appendix 353
List of Tables
Number of Products under Development for Neuroblastoma, H2 2016 19 Number of Products under Development for Neuroblastoma - Comparative Analysis, H2 2016 20 Number of Products under Development by Companies, H2 2016 21 Number of Products under Development by Companies, H2 2016 (Contd..1) 22 Number of Products under Development by Companies, H2 2016 (Contd..2) 23 Number of Products under Development by Companies, H2 2016 (Contd..3) 24 Number of Products under Investigation by Universities/Institutes, H2 2016 26 Comparative Analysis by Late Stage Development, H2 2016 27 Comparative Analysis by Clinical Stage Development, H2 2016 28 Comparative Analysis by Early Stage Development, H2 2016 29 Products under Development by Companies, H2 2016 30 Products under Development by Companies, H2 2016 (Contd..1) 31 Products under Development by Companies, H2 2016 (Contd..2) 32 Products under Development by Companies, H2 2016 (Contd..3) 33 Products under Development by Companies, H2 2016 (Contd..4) 34 Products under Investigation by Universities/Institutes, H2 2016 35 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 36 Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H2 2016 37 Neuroblastoma - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 38 Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H2 2016 39 Neuroblastoma - Pipeline by Alissa Pharma, H2 2016 40 Neuroblastoma - Pipeline by Ampio Pharmaceuticals Inc, H2 2016 41 Neuroblastoma - Pipeline by APEIRON Biologics AG, H2 2016 42 Neuroblastoma - Pipeline by AstraZeneca Plc, H2 2016 43 Neuroblastoma - Pipeline by Bayer AG, H2 2016 44 Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 45 Neuroblastoma - Pipeline by Bexion Pharmaceuticals LLC, H2 2016 46 Neuroblastoma - Pipeline by BioLineRx Ltd, H2 2016 47 Neuroblastoma - Pipeline by Bionucleon Srl, H2 2016 48 Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H2 2016 49 Neuroblastoma - Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016 50 Neuroblastoma - Pipeline by Cebiotex SL, H2 2016 51 Neuroblastoma - Pipeline by Celgene Corp, H2 2016 52 Neuroblastoma - Pipeline by Cielo Therapeutics Inc, H2 2016 53 Neuroblastoma - Pipeline by Cleveland BioLabs Inc, H2 2016 54 Neuroblastoma - Pipeline by Codagenix, Inc., H2 2016 55 Neuroblastoma - Pipeline by CorMedix Inc, H2 2016 56 Neuroblastoma - Pipeline by Curis Inc, H2 2016 57 Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 58 Neuroblastoma - Pipeline by DEKK-TEC Inc, H2 2016 59 Neuroblastoma - Pipeline by EnGeneIC Ltd, H2 2016 60 Neuroblastoma - Pipeline by Errant Gene Therapeutics LLC, H2 2016 61 Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 62 Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H2 2016 63 Neuroblastoma - Pipeline by Green Cross Cell Corp, H2 2016 64 Neuroblastoma - Pipeline by Ignyta Inc, H2 2016 65 Neuroblastoma - Pipeline by Incuron, LLC, H2 2016 66 Neuroblastoma - Pipeline by Juno Therapeutics Inc, H2 2016 67 Neuroblastoma - Pipeline by Kolltan Pharmaceuticals Inc, H2 2016 68 Neuroblastoma - Pipeline by Lindis Biotech GmbH, H2 2016 69 Neuroblastoma - Pipeline by MabVax Therapeutics Holdings Inc, H2 2016 70 Neuroblastoma - Pipeline by MediaPharma srl, H2 2016 71 Neuroblastoma - Pipeline by Merck & Co Inc, H2 2016 72 Neuroblastoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 73 Neuroblastoma - Pipeline by Morphogenesis Inc, H2 2016 74 Neuroblastoma - Pipeline by Novartis AG, H2 2016 75 Neuroblastoma - Pipeline by Novogen Ltd, H2 2016 76 Neuroblastoma - Pipeline by OGD2 Pharma SAS, H2 2016 77 Neuroblastoma - Pipeline by Pfizer Inc, H2 2016 78 Neuroblastoma - Pipeline by Pharmacyclics Inc, H2 2016 79 Neuroblastoma - Pipeline by Progenics Pharmaceuticals Inc, H2 2016 80 Neuroblastoma - Pipeline by ProNAi Therapeutics Inc, H2 2016 81 Neuroblastoma - Pipeline by Recombio SL, H2 2016 82 Neuroblastoma - Pipeline by Ribomic Inc., H2 2016 83 Neuroblastoma - Pipeline by Sapience Therapeutics Inc, H2 2016 84 Neuroblastoma - Pipeline by Sareum Holdings Plc, H2 2016 85 Neuroblastoma - Pipeline by Shionogi & Co Ltd, H2 2016 86 Neuroblastoma - Pipeline by Syros Pharmaceuticals Inc, H2 2016 87 Neuroblastoma - Pipeline by Tiltan Pharma Ltd, H2 2016 88 Assessment by Monotherapy Products, H2 2016 89 Assessment by Combination Products, H2 2016 90 Number of Products by Stage and Target, H2 2016 92 Number of Products by Stage and Mechanism of Action, H2 2016 98 Number of Products by Stage and Route of Administration, H2 2016 104 Number of Products by Stage and Molecule Type, H2 2016 106 Neuroblastoma - Dormant Projects, H2 2016 350 Neuroblastoma - Dormant Projects (Contd..1), H2 2016 351 Neuroblastoma - Dormant Projects (Contd..2), H2 2016 352 Neuroblastoma - Dormant Projects (Contd..3), H2 2016 353 Neuroblastoma - Discontinued Products, H2 2016 354
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
